Navigation Links
Hemispherx Presents Evidence of Ampligen Synergies with Existing,Antivirals at International Avian Influenza Conference

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development of new drug entities for the treatment of pandemic disease threats, announced today a new scientific report on the activity of its experimental therapeutic Ampligen(R) in combination with approved anti-influenza agents against highly pathogenic avian influenza (HPAI), also known as bird flu.

Tamiflu resistance by newly emerging strains of HPAI has been widely reported (New Engl. Journal Medicine vol. 353: page 2667, 2005) and has provided impetus for new ways to implement an antiviral counter-attack strategy.

In in vitro studies, Ampligen(R), an experimental therapeutic, was combined with the neuraminidase inhibitors Oseltamivir, (brand name Tamiflu) and with Zanamivir (Relenza) and thereafter applied to cells in culture infected with an H5N1 strain of HPAI. Three days following infection, cell viability and synergy analyses were performed.

Both Ampligen(R) and the neuraminidase inhibitors exhibited dose responses in the inhibition of the adverse effects of HPAI on cell cultures. Moreover, the combination of Ampligen(R) with oseltamivir at doses exceeding a certain threshold showed synergistic inhibition of viral induced cell destruction, and similar synergistic results were seen with the combination of Ampligen(R) with zanamivir.

The study results are being presented at the ongoing 2nd International Conference on Avian Influenza, being held at the Pasteur Institute.

While it is widely recognized that HPAI is a major, global public health concern, existing antiviral monotherapies can rapidly lead to drug-resistant strains of virus. Therefore, the Hemispherx study was conducted to establish a potentially pivotal role for Ampligen as part of a potentially effective combination therapy. Ampligen(R) is a novel double-stranded RNA experimental thera peutic that exhibits antiviral activity by different mechanisms than either Tamiflu or Relenza; it has completed Phase III clinical testing for another disorder, Chronic Fatigue Syndrome (CFS).

"With so few lines of defense currently available against avian influenza, it is crucial to discover lasting ways to extend and enhance the effectiveness of existing therapies, as has been done historically with other devastating viral diseases including HIV/AIDS and hepatitis," commented Dr. William Carter, Chairman and Chief Executive Officer of Hemispherx. "We are pleased to share the results of our studies of combination therapies involving Ampligen(R) and look forward to accelerating this development program under the "animal rule" for fast tracking experimental therapeutics for life threatening disorders." Under the "animal rule," extensive clinical studies can be replaced by animal model studies to evaluate efficacy under certain circumstances.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) and the experimental therapeutics Ampligen(R) and Oragens(R). Alferon N Injection(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information cont ained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.

Contact

Hemispherx Biopharma, Inc.
Dianne Will, 518-398-6222
ir@hemispherx.net
or
Sean Collins, 310-477-9800
Sr. Partner
CCG Investor Relations


'"/>




Related medicine technology :

1. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... The U.S. Food and Drug Administration today ... the risk of cardiovascular death in adult patients with ... "Cardiovascular disease is a leading cause of death ... Jean-Marc Guettier , M.D., C.M., director of the Division ... Drug Evaluation and Research. "Availability of antidiabetes therapies that ...
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 02, 2016 , ... Metabolic Code ... to nutraceuticals and help doctors more efficiently manage their practice. Power2Practice is ... software platform for Integrative and Functional Medicine. , The Metabolic Code platform ...
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known ... for in a show called "Front Page". One of the forthcoming episodes examines mammogram ... rates have plummeted in large part due to early detection. Like any other disease, ...
(Date:12/4/2016)... ... December 04, 2016 , ... ... new attractive animation styles with unique displacement design elements," said Christina Austin - ... third designs. Choose from a variety of design styles that include both left ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... Responsible dental ... One must brush properly to achieve optimal results. This important necessity inspired an inventor ... need for a way to ensure that people break or avoid bad techniques of ...
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
Breaking Medicine News(10 mins):